The first evidence derives from a monocentric study that evaluated the potential of parallel serial assessment of somatic mutation and methylation profile in monitoring the response to osimertinib in patients with stage IV lung adenocarcinoma and EGFR T790M mutation. The gene discussed is EGFR; the disease is lung adenocarcinoma.